• Reading EdU and CDK1–APE1 Evidence Carefully

  2026-10-12

  The supplied evidence links a vendor-described EdU/Cy5 flow-cytometry concept with a recent mechanistic study of CDK1–APE1 signaling in NSCLC, but it does not establish that the assay was used in that study or that its performance claims have been independently validated. The main evidence gaps concern assay benchmarking, causal interpretation of DNA-synthesis measurements, model breadth, and the distance between cell-based findings and clinical relevance.

• Phillygenin and AO/PI Evidence in Diabetic Nephropathy

  2026-10-12

  A 2025 preclinical study reported that phillygenin reduced inflammatory and apoptotic markers in cultured mouse podocytes and improved kidney-related outcomes in diabetic mice. AO/PI Staining Solution provides a conceptual live–dead fluorescence readout based on membrane integrity, but the supplied evidence does not establish that this reagent was used in the study or that such a readout can prove the proposed molecular mechanism.

• Cefepime (BMY-28142): Research Context and Evidence

  2026-10-11

  This overview places Cefepime (BMY-28142) in context as a research subject, distinguishing supplier descriptions from peer-reviewed evidence. It compares the available cefiderocol data with questions relevant to cefepime, including antimicrobial activity, resistance interpretation, central nervous system infection research, bacterial infection models, and neurotoxicity studies.

• ABT-199 and Senescent Microglia: Five Key Questions

  2026-10-10

  A source-grounded overview of ABT-199, senescent microglia, mitochondrial apoptosis, evidence quality, and the limits of extending mouse brain findings to human disease.

• Asunaprevir (BMS-650032): Evidence Overview

  2026-10-09

  Asunaprevir, also known as BMS-650032, is an HCV NS3/4A protease inhibitor studied for its effects on viral polyprotein processing and HCV RNA replication. Available supplied evidence supports a biochemical and cellular antiviral research rationale, but it does not establish broad clinical efficacy, direct activity in NUT carcinoma, or a validated role in caspase signaling.

• Firefly Luciferase mRNA: Evidence and Research Context

  2026-10-09

  This overview explains how Firefly Luciferase mRNA and 5-moUTP modified mRNA are used conceptually as transient expression reporters, while assessing what current lipid nanoparticle evidence can—and cannot—establish about delivery, translation, and immune recognition.

• miR-4769-3p, USP18/VDAC2, and SSc Adipogenesis

  2026-10-08

  Tang et al. identify miR-4769-3p as a regulator of subcutaneous adipose tissue loss in systemic sclerosis and connect it to the USP18/VDAC2 pathway. The study combines patient observations, a bleomycin-induced mouse model, and adipocyte-cell experiments to support a mechanistic link between microRNA activity, VDAC2 stability, and adipogenesis, while leaving clinical translation unresolved.

• Phillygenin and Signaling in Diabetic Nephropathy

  2026-10-08

  A 2025 Phytomedicine study links phillygenin with reduced inflammation, podocyte injury, and apoptosis in diabetic nephropathy models. Its main contribution is a multi-level analysis connecting TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling with renal outcomes, while its preclinical design leaves questions about causality and clinical translation.

• BAP1, Disulfidptosis, and Translational Strategy

  2026-10-07

  A source-grounded perspective on how BAP1, SLC7A11, cystine handling, and NADPH balance shape disulfidptosis research—and what translational teams should validate before advancing pathway or compound claims.

• AO/PI Staining Solution for DN Cell Analysis

  2026-10-07

  AO/PI Staining Solution supports fluorescence-based cell counting by pairing acridine orange and propidium iodide for membrane-integrity-based live/dead discrimination. This article explains how the readout can strengthen diabetic nephropathy research while clarifying what it can—and cannot—prove about inflammation, apoptosis, and therapeutic response.

• HDAC Inhibitors Repress NUT Carcinoma Programs

  2026-10-06

  Shiota et al. used a dCas9-based transcriptional reporter screen to identify structurally diverse HDAC inhibitors that suppress NUT-driven transcription. The study connects HDAC inhibition with loss of BRD4-NUT megadomain activity, tumor-cell differentiation, and growth control, while also showing enhanced effects when combined with bromodomain inhibition in xenograft models.

• Exogenous NADH Potentiates Antibiotics Against E. tarda

  2026-10-06

  A 2024 Virulence study reports that exogenous NADH reprogrammed Edwardsiella tarda metabolism, increased ATP-associated energy metabolism, and strengthened neomycin activity. The findings support metabolic potentiation as a research strategy, but the evidence remains primarily culture-based and requires validation across strains, hosts, exposure contexts, and safety endpoints.

• Grazoprevir Hydrate: From Protease Biology to Translation

  2026-10-05

  A source-grounded perspective on Grazoprevir hydrate and MK-5172 hydrate, connecting NS3/4A protease biology with genotype-aware validation, resistance research, and translational strategy.

• DRB: Research Context, Mechanisms, and Limits

  2026-10-05

  DRB is a research compound used to study transcriptional elongation and cyclin-dependent kinase activity. This overview compares supplier-reported biochemical and cellular findings with peer-reviewed evidence on YTHDF1-driven stem-cell fate transitions, emphasizing mechanistic boundaries, evidence strength, and the absence of direct evidence connecting DRB to that transdifferentiation model.

• Parthenolide, ROS, and Lymphoid Cancer Apoptosis

  2026-10-04

  Jorge and colleagues used a resazurin-based cell viability assay alongside flow cytometry and gene-expression analysis to examine parthenolide responses across seven lymphoid malignancy cell lines. The study links reduced metabolic activity with apoptosis, oxidative stress, glutathione loss, and mitochondrial membrane-potential disruption, while showing that response mechanisms vary by cell line.

8075 records 2/539 page Previous Next 12345 下5页 Last page